Six months prior, the U.S. Food & Drug Administration (FDA)
approved sofosbuvir, an oral medication shown to cure most cases of hepatitis C infection, with fewer side effects than the current treatment options.
The U.S. Food and Drug Administration (FDA) has not yet
approved sofosbuvir.
Not exact matches
Gilead Sciences» first offering, Sovaldi (
sofosbuvir), was
approved in the U.S. in December.
The team investigated an antiviral drug called
sofosbuvir,
approved and marketed under the brand name Sovaldi to treat and cure hepatitis C infections.
The ledipasvir /
sofosbuvir combination, Harvoni ®, is now FDA -
approved for numerous types of HCV infection, including the most common form in the US and Europe.